Theriva Biologics Inc.
$ 0.19
-1.70%
26 Dec - close price
- Market Cap 6,454,400 USD
- Current Price $ 0.19
- High / Low $ 0.19 / 0.18
- Stock P/E 0.09
- Book Value 0.65
- EPS 2.06
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.29 %
- ROE -1.67 %
- 52 Week High 2.03
- 52 Week Low 0.17
About
Theriva Biologics Inc. (TOVX) is a clinical-stage biotechnology company based in Rockville, Maryland, dedicated to addressing significant unmet medical needs through the development of innovative biologic therapies. Utilizing its proprietary technology platforms, Theriva is focused on creating targeted treatment solutions that enhance patient outcomes across various therapeutic areas. With a robust pipeline and an experienced management team, the company is well-equipped to advance its promising candidates, positioning itself as a key player in the evolving healthcare landscape.
Analyst Target Price
$7.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-12 | 2025-08-11 | 2025-05-05 | 2025-03-24 | 2024-11-11 | 2024-08-13 | 2024-05-07 | 2024-03-25 | 2023-11-13 | 2023-08-08 | 2023-05-11 | 2023-03-30 |
| Reported EPS | -0.45 | -1.93 | -1.55 | -11.49 | -6.8107 | -10.75 | -0.3 | -0.34 | -0.19 | -0.34 | -0.3 | -0.33 |
| Estimated EPS | -1.13 | -1.08 | -1.56 | -7.22 | -5.25 | -0.28 | -0.34 | -0.41 | -0.37 | -0.36 | -0.32 | -0.33 |
| Surprise | 0.68 | -0.85 | 0.01 | -4.27 | -1.5607 | -10.47 | 0.04 | 0.07 | 0.18 | 0.02 | 0.02 | 0 |
| Surprise Percentage | 60.177% | -78.7037% | 0.641% | -59.1413% | -29.7276% | -3739.2857% | 11.7647% | 17.0732% | 48.6486% | 5.5556% | 6.25% | 0% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TOVX
2025-12-29 13:49:41
Theriva Biologics Inc. stock surged 25.4% in premarket trading after the European Medicines Agency (EMA) provided positive scientific advice on the company's proposed Phase 3 clinical trial design for VCN-01 in pancreatic cancer treatment. The EMA agreed with key elements of the trial design, including sample size and a "macrocycle" dosing regimen allowing for multiple doses of VCN-01. Theriva plans to engage with the FDA in early 2026 to finalize the protocol for the multinational Phase 3 trial and is also seeking advice for a potential Phase 2/3 trial for VCN-01 in retinoblastoma.
2025-12-29 13:09:41
Theriva Biologics has received positive advice from the European Medicines Agency (EMA) on the Phase 3 trial design for VCN-01 in metastatic pancreatic ductal adenocarcinoma (PDAC), confirming the trial will incorporate an adaptive design. The company plans to meet with the FDA in the first half of 2026 to finalize the trial design, with its cash runway expected to support activities until Q1 2027. VCN-01 has already been granted Orphan Drug and Fast Track designations in the US and Europe.
2025-12-29 13:09:41
Theriva Biologics (TOVX) has received positive scientific advice from the European Medicines Agency's CHMP regarding the design of its planned Phase 3 trial for VCN-01 in first-line metastatic pancreatic adenocarcinoma. The CHMP's advice indicates that a single, randomized, placebo-controlled Phase 3 study, demonstrating a compelling benefit-risk profile, would support a future marketing authorization application. Key elements of the trial design, including overall survival as the primary endpoint and an adaptive dosing strategy, were agreed upon, aligning with previous Phase 2b data that showed VCN-01 improving overall survival, progression-free survival, and duration of response.
2025-12-29 13:09:41
Theriva Biologics (NYSE American: TOVX) has received positive scientific advice from the European Medicines Agency (EMA) regarding the design of its Phase 3 clinical trial for VCN-01 in metastatic pancreatic ductal adenocarcinoma (PDAC). The EMA's CHMP agreed on key aspects including overall survival as the primary endpoint and supported repeated "macrocycle" dosing. This endorsement helps pave the way for an End-of-Phase 2 meeting with the FDA in H1 2026 to finalize the multinational Phase 3 trial design.
2025-12-29 13:09:41
Theriva™ Biologics has announced that the European Medicines Agency (EMA) provided positive scientific advice on the design of a Phase 3 trial for VCN-01 in metastatic Pancreatic Ductal Adenocarcinoma (PDAC). The EMA agreed with key aspects of the trial, including sample size, repeated dosing, and an adaptive design, and recognized the improved overall survival with multiple VCN-01 doses. Theriva plans to meet with the FDA in H1 2026 to finalize the multinational Phase 3 trial design and pursue partnerships, with cash runway extending into Q1 2027.
2025-12-16 17:08:42
Theriva Biologics has rescheduled its special stockholder meeting. Further details about the reasons for the rescheduling or the new meeting date were not provided in this brief update.
